Inflammatory biomarkers in patients with sciatica: a systematic review

Maarten J Jungen, Bastiaan C Ter Meulen, Tim van Osch, Henry C Weinstein, Raymond W J G Ostelo, Maarten J Jungen, Bastiaan C Ter Meulen, Tim van Osch, Henry C Weinstein, Raymond W J G Ostelo

Abstract

Background: This systematic review focusses on inflammation as an underlying pathogenic mechanism in sciatica. We addressed two questions in particular: (1) what inflammatory biomarkers have been identified in patients with sciatica in the literature so far? 2) is there an association between the level of inflammatory activity and clinical symptoms?

Methods: The search was conducted up to December 19th 2018 in MEDLINE, EMBASE, CENTRAL and Web of Science. The study selection criteria: (1) observational cohort studies, cross-sectional studies and randomized clinical trials (RCT), (2) adult population (≥ 18 years) population with sciatica, (3) concentrations of inflammatory biomarkers measured in serum, cerebrospinal fluid (CSF) or biopsies, and (4) evaluation of clinically relevant outcome measures (pain or functional status). Three reviewers independently selected studies and extracted data regarding the study characteristics and the outcomes. Risk of Bias was evaluated using an adjusted version of the Quality in Prognosis Studies (QUIPS) tool.

Results: In total 16 articles fulfilled the criteria for inclusion: 7 cross sectional observational studies and 9 prospective cohort studies that included a total of 1212 patients. With regard to question 1) the following markers were identified: interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, IL-21, tumor necrosis factor-α (TNF-α), phospholipase A2, high sensitivity C-reactive protein (hsCRP), C-X-C motif chemokine 5 (CXCM5), CX3CL1, CCL2, epidermal growth factor (EGF), and monocyte chemotactic protein 4 (MCP-4). With regard to question 2) several positive correlations were found in longitudinal studies: a strong positive correlation between inflammatory mediators or byproducts and pain (measured by visual analogue scale, VAS) was found for IL-21 in two studies (r > 0,8), and moderate positive correlations for TNF-a in both serum (r = 0,629) and biopsy (r = 0.65); severe pain (VAS > 4) is associated with increased hsCRP levels among patients with sciatica (adjusted OR = 3.4 (95% CI, 1.1 to 10).

Conclusion: In this systematic review there was considerable heterogeneity in the type of biomarkers and in the clinical measurements in the included studies. Taking into account the overall risk of bias of the included studies there is insufficient evidence to draw firm conclusions regarding the relationship between inflammation and clinical symptoms in patients with sciatica.

Keywords: Biomarkers; Cytokines; Inflammation; Interleukin; Lumbar disc herniation; Sciatica; Systematic review.

Conflict of interest statement

Ethics approval and consent to participate

“Not applicable” (literature study).

Consent for publication

“Not applicable” as our manuscript does not contain any individual person’s data in any form.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flowchart of systematic review

References

    1. Ropper Allan H., Zafonte Ross D. Sciatica. New England Journal of Medicine. 2015;372(13):1240–1248. doi: 10.1056/NEJMra1410151.
    1. Spijker-Huiges A, Groenhof F, Winters JC, van Wijhe M, Groenier KH, van der Meer K. Radiating low back pain in general practice: incidence, prevalence, diagnosis, and long-term clinical course of illness. Scand J Prim Health Care. 2015;33(1):27–32. doi: 10.3109/02813432.2015.1006462.
    1. Lambeek LC, van Tulder MW, Swinkels IC, Koppes LL, Anema JR, van Mechelen W. The trend in total cost of back pain in the Netherlands in the period 2002 to 2007. Spine (Phila Pa 1976) 2011;36(13):1050–1058. doi: 10.1097/BRS.0b013e3181e70488.
    1. Porchet F, Wietlisbach V, Burnand B, Daeppen K, Villemure JG, Vader JP. Relationship between severity of lumbar disc disease and disability scores in sciatica patients. Neurosurgery. 2002;50:1253–1259.5.
    1. El Barzouhi A, Vleggeert-Lankamp CL, Nijeholt GJ LÀ, Van der Kallen BF, van den Hout WB, Jacobs WC, Koes BW, Peul WC, Leiden-The Hague Spine Intervention Prognostic Study Group Magnetic resonance imaging in follow-up assessment of sciatica. N Engl J Med. 2013;368(11):999–1007. doi: 10.1056/NEJMoa1209250.
    1. Khan AN, Jacobsen HE, Khan J, Filippi CG, Levine M, Lehman RA, Jr, Riew KD, Lenke LG, Chahine NO. Inflammatory biomarkers of low back pain and disc degeneration: a review. Ann N Y Acad Sci. 2017;1410(1):68–84. doi: 10.1111/nyas.13551.
    1. Wuertz K, Haglund L. Inflammatory mediators in intervertebral disk degeneration and discogenic pain. Global Spine J. 2013;3(3):175–184. doi: 10.1055/s-0033-1347299.
    1. Podichetty VK. The aging spine: the role of inflammatory mediators in intervertebral disc degeneration. Cell Mol Biol (Noisy-le-grand) 2007;53(5):4–18.
    1. Baron R, Binder A. Et. al. neuropathic low back pain in clinical practice. Eur J Pain. 2016;20(6):861–873. doi: 10.1002/ejp.838.
    1. Moher David, Liberati Alessandro, Tetzlaff Jennifer, Altman Douglas G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
    1. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–286. doi: 10.7326/0003-4819-158-4-201302190-00009.
    1. Den Bakker CM, Anema JR, Zaman AGNM, de Vet HCW, Sharp L, Angenete E, Allaix ME, Otten RHJ, Huirne JAF, Bonjer HJ, de Boer AGEM, Schaafsma FG. Prognostic factors for return to work and work disability among colorectal cancer survivors; a systematic review. PLoS One. 2018;13(8):e0200720. doi: 10.1371/journal.pone.0200720.
    1. Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 5. Boston: Houghton Mifflin; 2003.
    1. Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Communications in Statistics - Simulation and Computation. 2010;39(4):860–864. doi: 10.1080/03610911003650383.
    1. Schistad EI, Espeland A, Pedersen LM, Sandvik L, Gjerstad J, Røe C. Association between baseline IL-6 and 1-year recovery in lumbar radicular pain. Eur J Pain. 2014;18(10):1394–1401. doi: 10.1002/j.1532-2149.2014.502.x.
    1. Piperno M, Hellio le Graverand MP, Reboul P, Mathieu P, Tron AM, Perrin G, Peschard MJ, Richard M, Vignon E. Phospholipase A2 activity in herniated lumbar discs. Clinical correlations and inhibition by piroxicam. Spine (Phila Pa 1976) 1997;22(18):2061–2065. doi: 10.1097/00007632-199709150-00001.
    1. Brisby H, Olmarker K, Larsson K, Nutu M, Rydevik B. Proinflammatory cytokines in, cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spine J. 2002;11(1):62. doi: 10.1007/s005860100306.
    1. Sugimori K, Kawaguchi Y, Morita M, Kitajima I, Kimura T. High-sensitivity analysis of serum C-reactive protein in young patients with lumbar disc herniation. J Bone Joint Surg Br. 2003;85(8):1151–1154. doi: 10.1302/0301-620X.85B8.14538.
    1. Cheng L, Fan W, Liu B, Wang X, Nie L. Th17 lymphocyte levels are higher in patients with ruptured than non-ruptured lumbar discs, and are correlated with pain intensity. Injury. 2013;44(12):1805–1810. doi: 10.1016/j.injury.2013.04.010.
    1. Xue H, Yao Y, Wang X, Zhang F, Jiang X, Liu J, Wang H, Li Y, Wang X, Li H, Zhang J. Interleukin-21 Is Associated with the Pathogenesis of Lumbar Disc Herniation. Iran J Allergy Asthma Immunol. 2015;14(5):509–518.
    1. Peng ZY, Chen R, Fang ZZ, Chen B, Wang ZH, Wang XY. Increased local expressions of CX3CL1 and CCL2 are related to clinical severity in lumbar disk herniation patients with sciatic pain. J Pain Res. 2017;10:157–116. doi: 10.2147/JPR.S125914.
    1. Palada V, Ahmed AS, Finn A, Berg S, Svensson CI, Kosek E. Characterization of euroinflammation and periphery-to-CNS inflammatory cross-talk in patients with disc herniation and degenerative disc disease. Brain Behav Immun. 2019;75:60–71. doi: 10.1016/j.bbi.2018.09.010.
    1. Stürmer T, Raum E, Buchner M, Gebhardt K, Schiltenwolf M, Richter W, Brenner H. Pain and high sensitivity C reactive protein in patients with chronic low back pain and acute sciatic pain. Ann Rheum Dis. 2005;64(6):921–925. doi: 10.1136/ard.2004.027045.
    1. Andrade P, Hoogland G, Teernstra OP, van Aalst J, van Maren E, Daemen MA, Visser-Vandewalle V. Elevated IL-1β and IL-6 levels in lumbar herniated discs in patients with sciatic pain. Eur Spine J. 2013;22(4):714–720. doi: 10.1007/s00586-012-2502-x.
    1. Andrade P, Visser-Vandewalle V, Philippens M, Daemen MA, Steinbusch HW, Buurman WA, Hoogland G. Tumor necrosis factor-α levels correlate with postoperative pain severity in lumbar disc hernia patients: opposite clinical effects between tumor necrosis factor receptor 1 and 2. Pain. 2011;152(11):2645–2652. doi: 10.1016/j.pain.2011.08.012.
    1. Pedersen LM, Schistad E, Jacobsen LM, Røe C, Gjerstad J. Levels of the pro-inflammatory interleukins 6 (IL-6) and −8 (IL-8) in patients with lumbar radicular pain due to disc herniation: a 12-month prospective study. Brain Behav Immun. 2015;46:132–136. doi: 10.1016/j.bbi.2015.01.008.
    1. Wang K, Bao JP, Yang S, Hong X, Liu L, Xie XH, Wu XT. A cohort study comparing the serum levels of pro- or anti-inflammatory cytokines in patients with lumbar radicular pain and healthy subjects. Eur Spine J. 2016;25(5):1428–1434. doi: 10.1007/s00586-015-4349-4.
    1. Moen A, Lind AL, Thulin M, Kamali-Moghaddam M, Røe C, Gjerstad J, Gordh T. Inflammatory serum protein profiling of patients with lumbar radicular pain one year after disc herniation. Int J Inflam. 2016;2016:3874964. doi: 10.1155/2016/3874964.
    1. Zu B, Pan H, Zhang XJ, Yin ZS. Serum levels of the inflammatory cytokines in patients with lumbar radicular pain due to disc herniation. Asian Spine J. 2016;10(5):843–849. doi: 10.4184/asj.2016.10.5.843.
    1. Chen B, Liu Y, Zhang Y, Li J, Cheng K, Cheng L. IL-21 is positively associated with intervertebral disc degeneration by interaction with TNF-α through the JAK-STAT signaling pathway. Inflammation. 2017;40(2):612–622. doi: 10.1007/s10753-017-0508-6.
    1. Kraychete DC, Sakata RK, Issy AM, Bacellar O, Santos-Jesus R, Carvalho EM. Serum cytokine levels in patients with chronic low back pain due to herniated disc: analytical cross-sectional study. Sao Paulo Med J. 2010;128(5):259–262. doi: 10.1590/S1516-31802010000500003.
    1. Weber KT, Alipui DO, Sison CP, Bloom O, Quraishi S, Overby MC, Levine M, Chahine NO. Serum levels of the proinflammatory cytokine interleukin-6 vary based on diagnoses in individuals with lumbar intervertebral disc diseases. Arthritis Res Ther. 2016;18:3. doi: 10.1186/s13075-015-0887-8.
    1. Xiaogang Miao, Quanshan Hou, Liping Zhang, Kaken Habaxi. The expression of cytokine and its significance for the intervertebral disks of Kazakhs. Journal of Clinical Laboratory Analysis. 2016;31(5):e22087. doi: 10.1002/jcla.22087.
    1. Rasmussen-Barr E, Held U, Grooten WJ, Roelofs PD, Koes BW, van Tulder MW, Wertli MM. Nonsteroidal anti-inflammatory drugs for sciatica: an updated Cochrane review. Spine (Phila Pa 1976) 2017;42(8):586–594. doi: 10.1097/BRS.0000000000002092.
    1. Pinto RZ, Maher CG, Ferreira ML, Hancock M, Oliveira VC, McLachlan AJ, Koes B, Ferreira PH. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Ann Intern Med. 2012;157:865–877. doi: 10.7326/0003-4819-157-12-201212180-00564.
    1. Chou R, Hashimoto R, Friedly J. Epidural corticosteroid injections for radiculopathy and spinal stenosis: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(5):373–381. doi: 10.7326/M15-0934.
    1. Vroomen PC, de Krom MC, Wilmink JT, Kester AD, Knottnerus JA. Lack of effectiveness of bed rest for sciatica. N Engl J Med. 1999;340:418–423. doi: 10.1056/NEJM199902113400602.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅